As of November 6, 2026, Context Therapeutics Inc. is a publicly traded company (Nasdaq: CNTX); its largest reported holder is Avidity Partners Management LP, with 8.7% on Schedule 13G/A of May 12, 2026, then Soleus Capital Master Fund, L.P. (7.6%) (Schedule 13G/A, May 12, 2026).
Is this your company?
About to sign with, pay or invest in Context Therapeutics Inc.? See the free Snapshot first.
Free to see. No signup.
Is Context Therapeutics Inc. a real, registered company?
- Context Therapeutics Inc. files with the SEC under CIK 1842952 (its SEC filings).
- Its shares are listed under the ticker CNTX on Nasdaq (SEC company record).
- Incorporated in Delaware; business address in Philadelphia, Pennsylvania, as its SEC filings state.
- Court and bankruptcy records: see Before you sign or pay below.
Before you sign or pay
- Court and bankruptcy: No federal court case or bankruptcy filing found under Context Therapeutics Inc. in our court records and SEC 8-K records (as of 2026-11-06).
- Ownership: 5%+ holders are reported on Schedule 13D or 13G; the latest names BlackRock (filed 2026-07-27).
Who are Context Therapeutics Inc.'s owners and officers?
Context Therapeutics Inc.: incorporated in Delaware; business address in Philadelphia, Pennsylvania; industry Pharmaceutical Preparations (Schedule 13G/A, 2026-08-14).
Officers and directors, each with the role and the filing that names them:
- : Executive Officer, Director (Form D, 2024-05-16)
- : Executive Officer (Form D, 2024-05-16)
- : Executive Officer (Form D, 2024-05-16)
- : Director (Form D, 2024-05-16)
- : Director (Form D, 2024-05-16)
- : Director (Form D, 2024-05-16)
- : Director (Form D, 2024-05-16)
| Report | Holder | Share |
|---|---|---|
| Schedule 13G/A, 2026-08-14 | Mpm Bioimpact LLC | 1.4% |
| Schedule 13G/A, 2026-08-12 | Blue Owl Capital Holdings LP | 3.19% |
| Schedule 13G/A, 2026-07-31 | Octagon Capital Advisors LP | 3.3% |
| Schedule 13G, 2026-07-27 | Blackrock, Inc. | 6.7% |
| Schedule 13G/A, 2026-05-15 | Great Point Partners, LLC | 2.44% |
| Schedule 13G/A, 2026-05-14 | Blue Owl Capital Holdings LP | 5.54% |
| Schedule 13G, 2026-05-14 | Octagon Capital Advisors LP | 5.7% |
| Schedule 13G/A, 2026-05-12 | Avidity Partners Management LP | 8.7% |
| Schedule 13G/A, 2026-05-08 | Soleus Capital Master Fund, L.P. | 7.6% |
| Schedule 13G/A, 2026-02-17 | Mpm Bioimpact LLC | 11.6% |
| Schedule 13G/A, 2026-02-17 | Great Point Partners, LLC | 5.1% |
| Schedule 13G, 2026-02-03 | Soleus Capital Master Fund, L.P. | 5.2% |
Questions about who owns Context Therapeutics Inc.
Who owns Context Therapeutics Inc.?
On this page, 3 holders' latest ownership filings report 5% or more of Context Therapeutics Inc.: Avidity Partners Management LP (8.7%, Schedule 13G/A, filed 2026-05-12), Soleus Capital Master Fund, L.P. (7.6%, Schedule 13G/A, filed 2026-05-08) and Blackrock, Inc. (6.7%, Schedule 13G, filed 2026-07-27).
Who are the largest shareholders of Context Therapeutics Inc.?
By the share each holder's latest filing reports, the largest holders of Context Therapeutics Inc. on this page are Avidity Partners Management LP (8.7%), Soleus Capital Master Fund, L.P. (7.6%) and Blackrock, Inc. (6.7%).
When did Avidity Partners Management LP buy into Context Therapeutics Inc.?
The filings give report dates, not purchase dates. The earliest filing from Avidity Partners Management LP on this page is the Schedule 13G/A, filed 2026-05-12, reporting 8.7%. That earliest filing is itself an amendment, which updates an earlier report.
Is this an audit or a full list?
Neither. The ownership list on this page covers only Schedule 13D and 13G filings, which holders make once they own 5% or more of a class of shares (an amendment can report a stake that has since fallen below 5%); 12 such filings are shown here. It is not an audit and not a full cap table: holders who never reached 5% are not listed, and a stake can change after its latest filing.
Want the whole picture on Context Therapeutics Inc.?
Example from a real report (our sample on Target): “Target eliminated approximately 1,800 corporate positions, with around 1,000 employees receiving layoff notices and the remainder accounted for by eliminating open roles.” Source: NBC News
A Full Report on Context Therapeutics Inc.: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on Context Therapeutics Inc. covers
The Short Answer
Which Company This Is
What They Do, And How The Money Works
Who Runs It, And How To Reach Them
The Money: Funding, Valuation, Runway
Who Pays Them, And Who They Are Up Against
Warning Bells
Sources
17 cited sources found
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
Which insiders own Context Therapeutics Inc. shares?
Directors, officers and holders of 10% or more report their shares on Forms 3, 4 and 5. Each line is the latest such report, largest holding first.
- , the chief executive and a director: 1,079,891 shares (1.2% of shares outstanding), 159,701 held directly and 920,190 indirectly (Form 4, 2025-06-10).
- , the chief legal officer and corp. sec: 81,983 shares (0.09% of shares outstanding), 29,000 held directly and 52,983 indirectly (Form 4, 2025-06-10).
- , the chief financial officer: 80,010 shares (0.09% of shares outstanding) (Form 4, 2025-06-10).
Shares outstanding: 91,879,177 as of 2026-08-03, from the company's latest SEC cover page.
How much has Context Therapeutics Inc. raised?
| Filed | Sold | Offered |
|---|---|---|
| Form D, 2024-05-16 | $99.99M | $100M |
Keep reading
More on Context Therapeutics Inc. and the records around it.
Context Therapeutics Inc. elsewhere on the record
- 5%+ stake filings Aug 2026
Companies that share a holder
- MPM BioImpact LLC also filed stake reports on 4 other companies: Climb Bio, Inc. (Aug 2026), DBV TECHNOLOGIES S.A. (Aug 2026), Forte Biosciences, Inc. (May 2026)
- Avidity Partners Management LP also filed stake reports on 5 other companies: Immunic, Inc. (Apr 2026), Perspective Therapeutics, Inc. (Mar 2026), Scynexis, Inc. (Feb 2026)
- Octagon Capital Advisors LP also filed stake reports on 8 other companies: Precision BioSciences, Inc. (Nov 2026), Corbus Pharmaceuticals Holdings, Inc. (May 2026), Dianthus Therapeutics, Inc. /DE/ (May 2026)
Related pages
Filings, cases and notices link to their records. A not-found line names the records searched; it is not proof of absence.
Not for employment, credit, insurance or tenancy decisions.
Cite this page
https://mentionfox.com/who-owns/context-therapeutics